b
lymphocyt
common
marmoset
callithrix
jacchu
immortalis
infect
epsteinbarr
viru
ebv
vitro
desgrang
et
al
c
jacchu
suscept
infect
blood
stage
sever
speci
malaria
parasit
includ
line
design
mitchel
et
al
recov
show
immun
reinfect
exploit
two
phenomena
ebvtransform
marmoset
lymphoblastoid
cell
line
secret
antibodi
malaria
parasit
antigen
gener
clone
believ
first
time
monoclon
antibodi
mab
rais
common
marmoset
sinc
numer
divers
human
pathogen
infect
small
primat
laboratori
method
may
prove
gener
applic
gener
mab
whose
specif
deriv
immun
respons
infect
monoclon
antibodi
mab
technolog
greatli
facilit
identif
antigen
complex
pathogen
mab
produc
anim
show
protect
immun
follow
infect
may
particular
relev
analys
abil
epsteinbarr
viru
ebv
transform
human
b
lymphocyt
pope
et
al
exploit
product
human
monoclon
antibodi
antigen
divers
viral
bacteri
eukaryot
pathogen
see
crawford
review
although
b
lymphocyt
common
marmoset
calli
thrix
jacchu
small
neotrop
primat
may
similarli
immortalis
infect
ebv
vitro
desgrang
et
al
exploit
phenomenon
mab
product
previous
report
evalu
c
jacchu
laboratori
host
plasmodium
vivax
wide
distribut
clinic
import
human
malaria
parasit
one
marmoset
infect
laboratori
line
p
vwax
first
observ
isol
morpholog
alter
virul
malaria
initi
consid
marmosetadapt
mutant
p
vivax
mitchel
et
al
recent
gene
sequenc
data
refut
assumpt
suggest
second
speci
malaria
parasit
contamin
origin
inoculum
formal
reidentif
hand
water
et
al
prepar
immunobiolog
malaria
infect
design
marmoset
virul
form
extens
studi
c
jacchu
primari
infect
selflimit
gener
high
titr
antimalari
immunoglobulin
g
igg
challeng
selfcur
anim
result
low
grade
abbrevi
parasitaemia
accompani
rise
antibodi
titr
mitchel
et
al
use
ebv
immortalis
splenic
lymphocyt
common
marmoset
recov
infect
malaria
clone
result
lymphoblastoid
cell
line
lcl
use
xirradi
ebvtransform
lcl
rais
naiv
marmoset
feeder
cell
monocion
marmoset
lcl
gener
shown
secret
antibodi
direct
malaria
antigen
mab
whose
specif
deriv
protect
immun
respons
understand
immunobiolog
model
system
marmoset
lcl
routin
maintain
rpmi
medium
gibcoflow
supplement
penicillin
gibco
streptomycin
gibco
heatinactiv
foetal
calf
serum
fc
seralab
iuml
gml
respect
hereinaft
refer
cultur
medium
transform
fungizon
gibco
nystatin
gibco
ad
cultur
medium
ttgml
uml
respect
penicillin
streptomycin
fc
level
doubl
cultur
medium
supplement
fc
also
use
establish
clonal
cultur
cultur
maintain
watersatur
atmospher
co
z
air
ebv
obtain
supernat
ebvtransform
saguinu
oedipu
lcl
miller
et
al
kind
gift
dr
crawford
ebvtransform
callithrix
jacchu
lcl
desgrang
et
al
kind
gift
dr
c
desgrang
lcl
routin
maintain
tissu
cultur
flask
nunc
expand
twice
weekli
twofold
dilut
cell
suspens
prior
harvest
viru
cultur
left
without
feed
day
callithrix
b
lymphocyt
less
suscept
transform
ebv
human
c
desgrang
person
commun
see
also
henderson
et
al
viruscontain
supernat
concentr
ultracentrifug
prior
use
thu
supernat
first
clarifi
lowspe
centrifug
follow
filtrat
pm
spun
g
h
pellet
ebv
virusrich
pellet
resuspend
fresh
cultur
medium
clarifi
supernat
c
desgrang
person
commun
start
volum
store
liquid
n
common
marmoset
callithrix
jacchu
bred
close
coloni
addit
sinc
none
anim
use
experi
previous
expos
malaria
parasit
ebv
infect
marmosetadapt
malaria
parasit
line
use
throughout
parasit
handl
enumer
previous
describ
mitchel
et
al
lymphocyt
transform
obtain
spleen
two
anim
malaria
induc
inocul
infect
blood
show
typic
cours
primari
infect
mitchel
et
al
marmoset
month
time
infect
singl
infect
show
peak
parasitaemia
day
post
infect
pi
fallen
bare
detect
level
time
anim
kill
day
pi
marmoset
month
time
infect
similar
initi
infect
rechalleng
six
time
day
pi
kill
day
final
rechalleng
first
rechalleng
produc
detect
parasitaemia
kill
spleen
marmoset
remov
serumfre
cultur
medium
hank
balanc
salt
solut
transport
rins
serumfre
cultur
medium
minc
push
stainless
steel
mesh
apertur
lymphocyt
purifi
ficollpaqu
pharmacia
wash
three
time
serumfre
cultur
medium
resuspend
cellsml
x
concentr
ebv
suspens
incub
h
cell
suspens
dilut
addit
fresh
cultur
medium
supplement
fungizon
nystatin
extra
penicillin
streptomycin
fc
seed
well
plate
linbro
surplu
isol
wash
lymphocyt
cryopreserv
store
liquid
n
use
standard
protocol
later
resuscit
follow
h
recoveri
period
cultur
medium
supplement
fc
transform
describ
transform
cultur
left
undisturb
day
day
interv
depend
rate
medium
acidif
cultur
medium
exchang
fresh
regim
continu
definit
popul
expans
appar
depend
growth
rate
cultur
expand
day
interv
mean
day
dilut
line
demonstr
consist
growth
regim
expans
twofold
dilut
everi
day
adopt
primari
cultur
screen
antimalaria
antibodi
day
post
transform
interv
thereaft
xirradi
ebvtransform
lcl
normal
anim
use
feeder
cell
gener
line
peripher
blood
lymphocyt
pbl
normal
marmoset
design
isol
ficolipaqu
wash
transform
describ
consist
growth
appar
feeder
cell
line
maintain
twiceweekli
dilut
x
cellsml
stock
ebv
use
gener
feeder
cell
line
design
respect
antibodysecret
cell
could
clone
presenc
feeder
cell
carri
strain
viru
appropri
feeder
cell
line
xirradi
r
dilut
suffici
fresh
cultur
medium
fc
yield
cellsml
medium
supplement
fc
thu
medium
partli
precondit
feeder
cell
cell
clone
ad
minim
volum
cultur
medium
tl
aliquot
result
cell
suspens
seed
flatbottom
well
plate
nunc
interv
medium
well
exchang
fresh
cultur
medium
case
addit
xirradi
feeder
cell
ad
well
first
medium
chang
antibodyproduc
lcl
routin
establish
primari
cultur
seed
equival
one
ten
cellswel
antimalaria
antibodysecret
lcl
transfer
ml
cultur
medium
well
well
plate
linbro
expand
twofold
dilut
cell
suspens
twice
weekli
lcl
expand
ml
beyond
reclon
establish
clone
maintain
twofold
dilut
everi
day
cultur
supernat
screen
antimalaria
antibodi
indirect
immunofluoresc
dri
unfix
thick
film
wash
mvfiinfect
marmoset
red
blood
cell
rbc
previous
describ
mitchel
et
al
conserv
antigen
minimis
screen
time
cocktail
fitcconjug
rabbit
antihuman
igg
dako
fitcconjug
sheep
antihuman
igm
serotec
previous
screen
reactiv
marmoset
igg
igm
respect
use
detect
bound
marmoset
antibodi
marmoset
monoclonai
antibodi
immun
marmoset
sera
characteris
immunoprecipit
antigen
crude
lysat
radiolabel
mvflinfect
rbc
precipit
antigen
separ
sdspage
identifi
fluorographi
ml
blood
mvflinfect
marmoset
parasitaemia
approxim
wash
serumfre
malaria
cultur
medium
rpmi
supplement
qe
mgml
dglucos
hypoxanthin
iuml
heparin
leo
laboratori
incub
ml
serumfre
methioninefre
malaria
cultur
medium
gibco
selectamin
plu
addit
supplement
mci
methionin
amersham
atmospher
n
co
h
rbc
extens
wash
store
cell
lysat
prepar
immunoprecipit
perform
method
holder
freeman
use
cpm
lysat
xl
cultur
supernat
zl
immun
marmoset
serum
per
reaction
immunoprecipit
complex
solubilis
separ
sdspage
reduc
condit
use
standard
protocol
gel
fix
stain
coomassi
blue
destain
impregn
ppo
dmso
dri
use
standard
protocol
dri
gel
place
preflash
xray
plate
kodak
xomat
incub
week
facilit
photograph
document
band
develop
fluorograph
intensifi
chromium
enhanc
use
standard
photograph
techniqu
fresh
splenic
lymphocyt
marmoset
frozen
resuscit
splenic
lymphocyt
marmoset
sucess
transform
monoclon
antimalaria
antibodysecret
lcl
gener
design
transform
respect
pbl
normal
marmoset
also
success
transform
provid
feeder
cell
line
clone
first
week
transform
cultur
show
consider
metabol
activ
necessit
regular
medium
chang
littl
increas
cell
number
cultur
first
expand
week
post
transform
pt
respect
routin
twice
weekli
expans
initi
approxim
week
pt
respect
subsequ
experi
transform
data
shown
suggest
expans
could
commenc
earlier
fc
level
reduc
week
fi
week
week
pt
antimalaria
antibodi
observ
supernat
primari
cultur
first
test
day
pt
still
present
day
pt
respect
supernat
primari
cultur
test
beyond
date
lost
detect
antimalaria
activ
sometim
day
pt
clone
xirradi
ebvtransform
pbl
normal
marmoset
prove
effect
feeder
cell
permit
clonal
growth
ebvtransform
antimalaria
antibodysecret
splenocyt
irradi
marmoset
lymphoblastoid
cell
show
littl
tendenc
break
remain
morpholog
intact
mani
week
irradi
thu
grow
clone
could
reliabl
detect
microscop
observ
well
plate
therefor
screen
immunofluoresc
antimalaria
antibodi
secret
lcl
sucess
rais
primari
cultur
subcul
ture
cellswel
day
pt
latest
time
attempt
subcultur
initi
day
pt
well
seed
cell
gave
rise
lcl
fc
level
reduc
supernat
screen
antimalaria
antibodi
week
post
seed
respect
approxim
rang
well
plate
seed
primari
cultur
equival
one
cellwel
found
posit
antimalaria
antibodi
howev
success
expand
yield
lcl
data
cultur
summaris
tabl
reclon
fc
level
reduc
supernat
screen
antimalaria
antibodi
week
post
seed
respect
clone
effici
determin
poisson
distribut
analysi
approxim
rang
tabl
summaris
data
cultur
neither
provis
addit
feeder
cell
week
post
clone
use
roundbottom
well
plate
seed
feeder
major
ebvtransform
marmoset
lymphoblastoid
cell
grow
suspens
either
singli
clump
diamet
cell
may
adopt
hand
mirror
shape
similar
ebvtransform
human
iymphocyt
howev
marmoset
lcl
differ
human
counterpart
passag
proport
cell
attach
floor
cultur
flask
spread
adopt
fibroblastoid
morpholog
provid
cell
densiti
kept
high
cellsmi
establish
polyclon
monoclon
marmoset
lcl
grow
readili
cultur
optim
condit
popul
doubl
time
short
day
seen
howev
twice
weekli
doubl
suitabl
routin
mainten
line
cultur
attain
densiti
x
cellsml
ebvtransform
monoclon
marmoset
lcl
stabl
longterm
cultur
growth
immunoglobulin
secret
maintain
year
continu
cultur
date
monoclon
line
characteris
studi
secret
igg
level
gml
cultur
supernat
small
number
lgmsecret
line
also
gener
although
less
well
characteris
immunoprecipit
studi
demonstr
marmoset
mab
rais
sever
distinct
parasit
antigen
fig
track
immunofluoresc
mab
localis
near
surfac
merozoit
fig
ontogeni
express
antigen
erythrocyt
schizogoni
role
elicit
clinic
immun
infect
common
marmoset
describ
elsewher
b
iymphocyt
common
marmoset
callithrixjacchu
immortalis
transform
ebv
desgrang
et
al
speci
suscept
infect
blood
stage
sever
speci
malaria
parasit
includ
line
design
mitchel
et
al
exploit
two
phenomena
develop
protocol
gener
ebvtransform
monoclon
lcl
secret
antimalaria
antibodi
marmoset
immun
malaria
parasit
although
mab
rais
nonhuman
primat
notabl
douroucouli
monkey
aotu
trivirgatu
stanley
rees
chimpanze
pan
troglodyt
van
meel
et
al
van
meur
jonker
unoki
believ
first
time
gener
common
marmoset
ebv
isol
cell
line
success
transform
pbl
naiv
marmoset
splenic
lymphocyt
mvflinfect
anim
cf
ishida
yamamoto
preliminari
evid
suggest
consider
difficult
transform
pbl
older
anim
year
data
shown
reason
unclear
although
similar
phenomenon
report
man
henderson
et
al
loss
antimalaria
antibodi
later
passag
primari
cultur
may
result
overgrowth
popul
specif
andor
nonproduc
cell
crawford
approxim
human
lymphocyt
polyclonallyactiv
ebv
vitro
fail
immortalis
tosato
et
al
transform
judg
onset
signific
popul
expans
appar
sever
week
exposur
marmoset
lymphocyt
viru
consequ
necessari
compromis
clone
late
signific
proport
popul
seed
consist
immortalis
cell
clone
earli
desir
specif
lost
overgrowth
rel
small
number
antimalaria
antibodysecret
lcl
gener
subcultur
primari
cultur
particular
failur
establish
line
cultur
seed
equival
one
ten
cell
per
well
day
pt
may
reflect
dilemma
fresh
marmoset
pbl
avail
suffici
number
use
feeder
cell
clone
xirradi
ebvtransform
lcl
deriv
normal
marmoset
pbl
prove
effect
suggest
growth
marmoset
lcl
may
subject
autocrin
stimul
see
also
tiebout
et
al
would
consist
observ
optim
growth
high
cell
densiti
abil
attach
spread
tissu
culturetr
surfac
characterist
ebvtransform
callithrix
cell
desgrang
et
al
indic
contamin
lcl
anoth
cell
type
ebvtransform
monoclon
marmoset
lcl
stabl
growth
antibodi
secret
maintain
mani
month
continu
cultur
human
system
major
clone
gener
ebvtransform
pbl
secret
igm
see
exampl
brown
miller
tosato
et
al
chan
et
al
predomin
lggsecret
clone
detect
studi
may
reflect
omiss
cultur
medium
believ
enhanc
surviv
igmsecret
human
lcl
often
ad
c
desgrang
person
commun
inhibit
growth
marmoset
lcl
data
shown
use
howev
result
thought
like
artefactu
result
greater
affin
antihuman
igg
use
screen
supernat
antimalaria
antibodi
marmoset
igg
antihuman
igm
use
marmoset
igm
therebi
bias
assay
toward
detect
lgg
antibodi
differ
suscept
transform
ebv
marmoset
human
b
lymphocyt
splenic
peripher
blood
b
lymphocyt
may
also
influenc
ratio
igg
secretor
igm
secretor
gener
techniqu
although
method
describ
paper
less
effici
convent
rodent
hybridoma
technolog
marmoset
mab
produc
possess
specif
deriv
protect
immun
respons
greatli
facilit
investig
immunobiolog
c
jacchusmvfl
model
system
mitchel
et
al
laboratori
primat
immunolog
studi
common
marmoset
possess
sever
use
characterist
small
easi
handl
requir
rel
simpl
husbandri
breed
readili
captiv
usual
bear
twin
haematopoiet
chimaera
furthermor
describ
gener
marmoset
mab
feasibl
c
jacchu
suscept
infect
divers
human
pathogen
major
clinic
import
includ
coronaviru
russel
et
al
junin
viru
avila
et
al
varicella
zoster
viru
provost
et
al
parainfluenza
type
sendai
viru
sunderland
et
al
htlv
type
kinoshita
et
al
ebv
wedderburn
et
al
campylobacterfetu
russel
et
al
legionella
pneumophila
baskervil
et
al
bordetella
bronchiseptica
baskervil
et
al
chlamydia
trachomati
johnson
et
al
mycoplasma
genitalum
taylorrobinson
et
al
trypanosoma
cruzi
scott
et
al
plasmodium
vioax
mitchel
et
al
plasmodium
brasilianum
simian
form
p
malaria
wedderburn
et
al
possibl
hiv
mcciur
et
al
protocol
detail
commun
may
therefor
find
applic
studi
wide
rang
human
diseas
